Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

Yee acknowledges that while this is a favorable development, Biogen does face certain challenges ... Yee covers the Healthcare sector, focusing on stocks such as Amgen, Gilead Sciences, and Scholar ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

Biogen will retain its commercial rights to ... The marketed biosimilars are versions of big-selling brands, including Amgen's Enbrel (etanercept), AbbVie's Humira (adalimumab), Johnson ...

It has been a shaky time for healthcare stocks, but that only presents a buying opportunity. The Health Care Select Sector ...

Amgen AMGN will report third-quarter 2024 results ... REGN will report third-quarter 2024 results on Oct. 31 Biogen BIIB has an Earnings ESP of +1.14% and a Zacks Rank #3. Biogen’s stock ...

Attend Pittcon 2025 in Boston to connect with global leaders in laboratory science and explore cutting-edge advancements in ...